Gao-Kai Li

Gao-Kai Li

Auto-generated profile, based on publicly available information

Gao-Kai Li

Department of Toxicology

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
BBBing Bai
Bing Bai
YLYing Liu
Ying Liu
XFXue-Mei Fu
Xue-Mei Fu
HQHai-Yan Qin
Hai-Yan Qin
GLGao-Kai Li
Gao-Kai Li
SSShillong Sun
Shillong Sun
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase involved in cell proliferation, invasion, angiogenesis, and metastasis in various cancers, including hepatocellular carcinoma (HCC). However, the role and molecular mechanisms of EZH2 in HCC radiosensitivity remain unclear. Here, we show that EZH2 is upregulated in HCC cells and the aberrantly overexpressed EZH2 is associated with the poor prognosis of HCC patients. Using miRNA databases, we identified miR‐138‐5p as a regulator of EZH2. We also found that miR‐138‐5p was suppressed by EZH2‐induced H3K27me3 in HCC cell lines. MiR‐138‐5p overexpression and EZH2 knockdown enhanced cellular radiosensitivity while inhibiting cell migration, invasion, and epithelial‐mesenchymal transition (EMT). Analysis of RNA‐seq datasets revealed that the hypoxia‐inducible factor‐1 (HIF‐1) signaling pathway was the main enrichment pathway for differential genes after miR‐138‐5p overexpression or EZH2 knockdown. Expression level of HIF‐1α was significantly suppressed after miR‐138‐5p overexpression or silencing of EZH2. HIF‐1α silencing mitigated resistance of HCC cells and inhibited EMT. This study establishes the EZH2/miR‐138‐5p/HIF‐1α as a potential therapeutic target for sensitizing HCC to radiotherapy.